Radiation oncology firm Elekta announced that Mosaiq Evaluate, a toolset that integrates radiation therapy treatment planning features into its Mosaiq oncology information system, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
The toolset unites plan and dose-review capabilities in a single software framework inside a patient chart, Elekta said. It allows the treatment team to review a plan from virtually any treatment planning system and for any treatment modality, and multiple plans can be compared.
In addition to creating a worklist of plans needing review, Mosaiq Evaluate enables the medical physicist to identify approved plan information side-by-side with all treatment fields, as well as to approve treatment fields directly from the plan worklist. Medical dosimetrists will also be able to use the plan worklist to identify approved plans, according to Elekta.
